(Z) -Orantinib
(Z) -Orantinib ((Z) -SU6668) is a potent, selective, orally active and ATP competitive inhibitor of Flk‐1/KDR, PDGFRβ, and FGFR1, with IC50s of 2.1, 0.008, and 1.2 μM, respectively. (Z) -Orantinib is a potent antiangiogenic and antitumor agent that induces regression of established tumors[1][2].
Product Specifications
CAS Number
210644-62-5
Product Name Alternative
(Z) -SU6668; (Z) -TSU-68
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335, H413
Target
FGFR; PDGFR; VEGFR
Type
Reference compound
Related Pathways
Protein Tyrosine Kinase/RTK
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/z-orantinib.html
Concentration
10mM
Purity
99.44
Solubility
DMSO : 50 mg/mL (ultrasonic)
Smiles
O=C(O)CCC1=C(C)NC(/C=C2C(NC3=C\2C=CC=C3)=O)=C1C
Molecular Formula
C18H18N2O3
Molecular Weight
310.35
Precautions
H302, H315, H319, H335, H413
References & Citations
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Phase 3
Isoform
PDGFRβ; VEGFR2/KDR/Flk-1
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
Flavin-containing monooxygenase Rabbit Polyclonal Antibody
